Rosario, Argentina
November 12, 2025

• Total revenues were $77.5 million in 1Q26
• Net loss was $7.5 million and Adjusted EBITDA1 was $13.6 million

Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal first quarter ended September 30, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted.

Financial & Business Highlights

• Total revenues were $77.5 million in 1Q26, a 17% decline year over year, reflecting the expected reduction from the seed model transition and the pruning of low-margin and working-capital-intensive sales.
• Gross profit was $36.2 million, a 3% reduction from last year, with gross margin expanding to 47% from 40%, driven by a more profitable product mix.
• Operating profit was $7.1 million for the quarter, net loss was $7.5 million and Adjusted EBITDA1 was $13.6 million. Operating profit and Adjusted EBITDA increased 200% and 61% year over year, respectively, reflecting margin expansion and cost discipline.
• Working capital continued to improve year over year and sequentially, despite first quarter’s seasonally high needs.

Management Review

Mr. Federico Trucco, Bioceres´ Chief Executive Officer, commented: “This quarter reflects clear progress on the priorities we set for the year: improve the quality of revenues, protect margins, and operate with discipline. Profitability improved and costs continued to decrease as we reduced exposure to low-margin activities and focused on a more efficient product mix. Argentina remains challenging, although conditions are showing early signs of normalization. In parallel, we are prioritizing actions that strengthen our capital structure and enhance financial flexibility. We will continue to focus on the fundamentals we control — margin quality, cost discipline, and working-capital efficiency — while positioning the Company for long-term resilience.”

Key Financial Metrics
Table 1: 1Q26 Key Financial Metrics

1Q26 Summary: Revenues totaled $77.5 million in 1Q26, a 17% decline versus the prior year. Revenue performance reflects both the planned reduction of low-margin and working-capital-intensive sales, as part of the strategic reset, and the impact of timing of sales in certain Latam markets, particularly Uruguay. In Argentina, while demand for select products showed improvement versus an unusually weak prior year, the recovery remains gradual.

Despite lower revenues, operating performance strengthened, supported by a more profitable product mix and lower operating expenses. Gross margin expanded significantly from 40% to 47%, and SG&A expenses decreased meaningfully year over year, reflecting restructuring initiatives and continued cost discipline.

Net loss was $7.5 million, compared to a loss of $6.2 million in 1Q25. Operating performance improved year over year, but higher financial costs and increased tax accruals led to a wider bottom-line loss. Adjusted EBITDA1 was $13.6 million, a 61% increase versus $8.5 million in 1Q25, driven by gross margin expansion and a reduction in operating costs.

For a full version of Bioceres’ first quarter 2026 earnings release, click here

1 Please refer to the “Use of non IFRS financial information” section at this end of this document on our use of Adjusted EBITDA and its reconciliation to the most comparable IFRS financial measure.

Website: https://investors.biocerescrops.com/home/default.aspx

Published: November 12, 2025